We are live on
!
Find out more
HVC
Healthcare Value Capital Portfolio holdings
AUM
$50.7M
Turnover
28.57%
1-Year Est. Return
24.72%
This Fund
S&P 500
This Quarter
Est. Return
-4.66%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$55.7M
AUM Growth
-$2.81M
(-4.8%)
Cap. Flow
-$4.01M
Cap. Flow
% of AUM
-7.2%
Top 10 Holdings %
Top 10 Hldgs %
88.36%
Holding
23
New
4
Increased
4
Reduced
–
Closed
6
Avg Time Held Equity + Options
0.6
years
Top 10 Avg Time Held Equity + Options
0.6
years
Top 20 Avg Time Held Equity + Options
0.6
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Assertio
ASRT
|
+$2.22M |
| 2 |
ProShares UltraShort NASDAQ Biotechnology
BIS
|
+$681K |
| 3 |
Standard BioTools
LAB
|
+$405K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMRI
Albany Molecular Research Inc
AMRI
|
+$4.24M |
| 2 |
Artivion
AORT
|
+$2.69M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$346K |
| 4 |
FCSC
Fibrocell Science Inc.
FCSC
|
+$39.3K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.94% |
| 2 | Miscellaneous | 34.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Pfizer
PFE
$168B
| $8.4M | 15.09% |
263,500
| – | – |
2014 Q1
13 quarters
|
|
|
NVLN
2
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $7.67M | 13.79% |
831,440
| – | – |
2016 Q4
2 quarters
|
|
|
3
DELISTED
Assertio
ASRT
| $5.91M | 10.61% |
9,167
+3,334
| +57% | +$2.22M |
2015 Q4
6 quarters
|
|
4
Gilead Sciences
GILD
$193B
| $5.31M | 9.54% |
75,000
| – | – |
2016 Q3
3 quarters
|
|
|
5
CALL
ProShares UltraShort NASDAQ Biotechnology
BIS
$2M
| $4.85M | 8.72% |
25,000
+21,875
| +700% | +$4.77M |
2016 Q4
2 quarters
|
|
|
6
CALL
Gilead Sciences
GILD
$193B
| $4.25M | 7.63% |
60,000
| – | – |
2016 Q3
3 quarters
|
|
|
7
PUT
Artivion
AORT
$1.06B
| $3.99M | 7.17% |
+200,000
| New | +$3.58M |
2017 Q2
0 quarters
|
|
|
AGN
8
DELISTED
Allergan plc
AGN
| $3.65M | 6.55% |
15,000
| – | – |
2016 Q4
2 quarters
|
|
9
CALL
ProShares VIX Short-Term Futures ETF
VIXY
$242M
| $2.66M | 4.78% |
+781
| New | +$3.01M |
2017 Q2
0 quarters
|
|
10
Teva Pharmaceutical Industries Limited
TEVA
$48.2B
| $2.49M | 4.48% |
75,000
| – | – |
2016 Q4
2 quarters
|
|
11
Amarin Corp
AMRN
$239M
| $1.81M | 3.26% |
22,500
| – | – |
2016 Q3
3 quarters
|
|
|
12
Standard BioTools
LAB
$249M
| $1.46M | 2.62% |
360,500
+85,500
| +31% | +$405K |
2017 Q1
1 quarter
|
|
|
13
CALL
DELISTED
Assertio
ASRT
| $1.07M | 1.93% |
1,667
| – | – |
2016 Q4
2 quarters
|
|
|
IMMU
14
CALL
DELISTED
Immunomedics Inc
IMMU
| $883K | 1.59% |
100,000
| – | – |
2017 Q1
1 quarter
|
|
|
15
ProShares UltraShort NASDAQ Biotechnology
BIS
$2M
| $606K | 1.09% |
+3,125
| New | +$681K |
2017 Q2
0 quarters
|
|
|
16
CALL
Standard BioTools
LAB
$249M
| $606K | 1.09% |
150,000
+100,000
| +200% | +$474K |
2017 Q1
1 quarter
|
|
|
FCSC
17
CALL
DELISTED
Fibrocell Science Inc.
FCSC
| $40K | 0.07% |
+2,000
| New | +$24.7K |
2017 Q2
0 quarters
|
|
|
18
Artivion
AORT
$1.06B
| – | – |
-150,000
| Closed | -$2.69M | – |
|
19
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$806B
| – | – |
-25,000
| Closed | -$5.89M | – |
|
|
FCSC
20
DELISTED
Fibrocell Science Inc.
FCSC
| – | – |
-3,185
| Closed | -$39.3K | – |
|
|
IPXL
21
CALL
DELISTED
Impax Laboratories, Inc.
IPXL
| – | – |
-200,000
| Closed | -$2.53M | – |
|
|
AMRI
22
DELISTED
Albany Molecular Research Inc
AMRI
| – | – |
-302,400
| Closed | -$4.24M | – |
|
|
ZGNX
23
DELISTED
Zogenix, Inc.
ZGNX
| – | – |
-31,850
| Closed | -$346K | – |
|
Similar funds
C
CC
FCOI
FCOI
BI
KC
SCIM
MCP
Healthcare Value Capital's Q2 2017 Portfolio in Review
As of Q2 2017, Healthcare Value Capital held 23 positions worth $55.7M, down 4.8% from $58.5M the previous quarter. Its ten largest holdings account for 88% of the portfolio.
Healthcare Value Capital withdrew a net $4.01M in Q2 2017, closing 6 positions. Its most notable exit was Albany Molecular Research Inc, an estimated $4.24M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 74% a quarter earlier, followed by Miscellaneous.
Against the trend, Healthcare Value Capital opened a new position in ProShares UltraShort NASDAQ Biotechnology worth $606K.
- Healthcare Value Capital's largest Q2 2017 buy was ProShares UltraShort NASDAQ Biotechnology: 3,125 shares worth $606K.
- Healthcare Value Capital added most to Assertio in Q2 2017, an estimated $2.22M increase.
- Healthcare Value Capital fully exited Albany Molecular Research Inc in Q2 2017, selling an estimated $4.24M.
- Healthcare Value Capital's ten largest holdings make up 88% of its $55.7M portfolio in Q2 2017.
- Healthcare Value Capital opened 4 new positions and closed 6 in Q2 2017.
- Healthcare Value Capital's portfolio value fell 4.8% quarter-over-quarter to $55.7M.
Based on Healthcare Value Capital's 13F filing for Q2 2017, filed 10 Aug 2017.